No Data
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Company
Revenue Breakdown
News
Plus Therapeutics Provides Company Update Today
Presentation at 2023 Virtual June Investor Summit to highlight clinical development progressAUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a
Plus Therapeutics Announces Topline Results From Recurrent Glioblastoma External Control Analysis at ASCO 2023
Plus Therapeutics' partnership with Medidata resulted in a valid historical control arm for the Company's Phase 1/2 clinical and potential Phase 3 trials evaluating rhenium (186Re) obisbemeda in recurrent glioblastoma
Plus Therapeutics to Present at the 2023 Virtual June Investor Summit
AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies